Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EPICS Therapeutics logo — EPICS is a drug discovery and development company for small...

EPICS Therapeutics

EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancer

Founded 2018 Belgium Belgium 30 employees Seed Total: $7.20M Biopharma, Health Care

General Information

Company Name EPICS Therapeutics
Founded Year 2018
Location Belgium Belgium +1
Employees 30
Industries Biopharma, Health Care
Funding Stage Seed
Social

Get notified when EPICS Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About EPICS Therapeutics

Epic Therapeutics is a biopharmaceutical startup based in Belgium, founded in 2018. The company is focused on developing small molecule drugs targeting RNA epigenetic mechanisms involved in cancer. Its mission is to address unmet medical needs in oncology by inventing novel clinical agents. The recent €7.20M Seed Round investment on 24 May 2018, led by S.R.I.W., signifies investor confidence in the potential of EPICS's innovative approach. The company's ability to balance risk and reward in their development and partnership strategies demonstrates a calculated approach to product development. With a clear focus on high value-added endpoints, EPICS is poised to make significant contributions to the field of cancer treatment.

Taxonomy: drug delivery, cancer therapeutics, RNA epigenetics, small molecule drugs, oncology research

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1 •••• •••• 24 May 2018

EPICS Therapeutics Alternatives & Competitors

EPICS Therapeutics vs
Ubiquigent Ltd
Ubiquigent Ltd United Kingdom

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as powerfu...

Grant
10 employees
Biotechnology
Compare EPICS Therapeutics vs Ubiquigent Ltd
EPICS Therapeutics vs
Saverna Therapeutics AG
Saverna Therapeutics AG Switzerland

Saverna Therapeutics aims to discover highly active, selective and cell-permeable molecules to targe...

Series Unknown
4 employees
AI, Health and Wellness
Compare EPICS Therapeutics vs Saverna Therapeutics AG
EPICS Therapeutics vs
ProfoundBio
ProfoundBio United States

An oncology biotherapeutics company

Series B
8 employees
Biotechnology, Health and Wellness
Compare EPICS Therapeutics vs ProfoundBio

FAQ About EPICS Therapeutics

EPICS is a drug discovery and development company for small molecule drugs targeting RNA epigenetic mecanisms of cancer
EPICS Therapeutics was founded in 2018.
EPICS Therapeutics is headquartered in Belgium.
EPICS Therapeutics operates in the following industries: Biopharma, Health Care.
EPICS Therapeutics has approximately 30 employees.
EPICS Therapeutics has completed 1 funding round, raising a total of $7.20M. The latest funding stage is Seed.
Top alternatives and competitors to EPICS Therapeutics include Ubiquigent Ltd, Saverna Therapeutics AG, ProfoundBio, Regulus Therapeutics, CELLIPSE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EPICS Therapeutics and Ubiquigent Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors EPICS Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes